Investigating the effects of oryzatensin on gut microbiota growth using a novel quantitative standard curve-fitting method: an ex-vivo study
-
Mahmood Alizadeh Sani
,
Aydin Aynehchi
,
Meisam Barati
,
Abed Ghavami
,
Elyas Nattagh Eshtivani
,
Amin MokariYamchi
,
Elnaz Vaghef-Mehrabany
,
Mehrangiz Ebrahimi-Mameghani
Abstract
Objective: Oryzatensin (ORZ) is a refractory, bioactive peptide that is isolated from rice. In the current study, we investigated the effect of ORZ on the growth of gut microbiota.
Methods: Ten apparently healthy subjects were enrolled in the current ex vivo study. Casual stool specimens were obtained from the subjects, then Enterobacteriaceae, Bacilaceae, and probiotic bacterial families were isolated using MAC, MYP, and MRS agars, respectively. The effect of exposure to different concentrations of ORZ (10-4, 10-5, 10-6, and 10-7 mol/L) on the growth of these bacteria was evaluated using the standard curve-fitting method, instead of standard qualitative methods such as MBC and MIC, because of the absence of detectable optical differences among the wells. The bacterial quantity was determined by evaluation of the suspensions turbidity at 492 to 630 nm.
Results: ORZ had an antibacterial effect and negatively controlled the growth of all isolated species compared with the control group. The inhibitory effect of ORZ was most significant at the dose of 10-7 mol/L (not significant at 10-5 and 10-6 mol/L and significant at 10-4 mol/L) for bifidobacteria and 10-4 mol/L for Enterobacteriaceae, Bacilaceae, and lactic acid bacteria.
Conclusion: The findings of the current study reveals that ORZ and possibly rice can reduce intestinal total bacterial count. Moreover, considering the carcinogenic effects of final metabolites of the enteral bacteria, such as free radicals, ORZ and rice may have an antineoplastic effect.
1. Bouglé D, Bouhallab S. Dietary bioactive peptides: human studies. Critical reviews in food science and nutrition. 2015(just-accepted):00-.
2. Korhonen H, Pihlanto A. Bioactive peptides: production and functionality. International dairy journal. 2006;16(9):945-60.
3. Sharma S, Singh R, Rana S. Bioactive peptides: a review. Int J Bioautomation. 2011;15(4):223-50.
4. Korhonen H. Milk-derived bioactive peptides: From science to applications. Journal of Functional Foods. 2009;1(2):177-87.
5. Scalbert A, Morand C, Manach C, Rémésy C. Absorption and metabolism of polyphenols in the gut and impact on health. Biomedicine & Pharmacotherapy. 2002;56(6):276-82.
6. Cardona F, Andrés-Lacueva C, Tulipani S, Tinahones FJ, Queipo-Ortuño MI. Benefits of polyphenols on gut microbiota and implications in human health. The Journal of nutritional biochemistry. 2013;24(8):1415-22.
7. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food sources and bioavailability. The American journal of clinical nutrition. 2004;79(5):727-47.
8. Déprez S, Brezillon C, Rabot S, Philippe C, Mila I, Lapierre C, et al. Polymeric proanthocyanidins are catabolized by human colonic microflora into low-molecular-weight phenolic acids. The Journal of nutrition. 2000;130(11):2733-8.
9. Takahashi M, Moriguchi S, Yoshikawa M, Sasaki R. Isolation and characterization of oryzatensin: a novel bioactive peptide with ileum-contracting and immunomodulating activities derived from rice albumin. Biochemistry and molecular biology international. 1994;33(6):1151-8.
10. Ohinata K, Suetsugu K, Fujiwara Y, Yoshikawa M. Suppression of food intake by a complement C3a agonist [Trp 5]-oryzatensin (5–9). Peptides. 2007;28(3):602-6.
11. Ohinata K, Yoshikawa M. Food intake regulation by central complement system. Current Topics in Complement II: Springer; 2008. p. 33-44.
12. Asakura H, Suzuki K, Kitahora T, Morizane T. Is there a link between food and intestinal microbes and the occurrence of Crohn's disease and ulcerative colitis? Journal of gastroenterology and hepatology. 2008;23(12):1794-801.
13. Marteau PR, de Vrese M, Cellier CJ, Schrezenmeir J. Protection from gastrointestinal diseases with the use of probiotics. The American journal of clinical nutrition. 2001;73(2):430s-6s.
14. Husebye E. The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy. 2005;51(Suppl. 1):1-22.
15. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. The American journal of gastroenterology. 2000;95(12):3503-6.
16. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? The American journal of clinical nutrition. 2006;83(6):1256-64.
17. Zeng M, Cui W, Zhao Y, Liu Z, Dong S, Guo Y. Antiviral active peptide from oyster. Chinese Journal of Oceanology and Limnology. 2008;26:307-12.
18. Gill HS, Doull F, Rutherfurd K, Cross M. Immunoregulatory peptides in bovine milk. British Journal of Nutrition. 2000;84(S1):111-7.
19. Pierce A, Legrand D, Mazurier J. Lactoferrin: a multifunctional protein. Medecine sciences: M/S. 2009;25(4):361-9.
20. Seelinger G, Merfort I, Wölfle U, Schempp CM. Anti-carcinogenic effects of the flavonoid luteolin. Molecules. 2008;13(10):2628-51.
21. McIntosh GH, Royle PJ, Le Leu RK, Regester GO, Johnson MA, Grinsted RL, et al. Whey proteins as functional food ingredients? International Dairy Journal. 1998;8(5):425-34.
22. Agyei D, Danquah MK. Industrial-scale manufacturing of pharmaceutical-grade bioactive peptides. Biotechnology Advances. 2011;29(3):272-7.
23. Takahashi M, Moriguchi S, Ikeno M, Kono S, Ohata K, Usui H, et al. Studies on the ileum-contracting mechanisms and identification as a complement C3a receptor agonist of oryzatensin, a bioactive peptide derived from rice albumin. Peptides. 1996;17(1):5-12.
24. Marshall SH, Arenas G. Antimicrobial peptides: A natural alternative to chemical antibiotics and a potential for applied biotechnology. Electronic Journal of Biotechnology. 2003;6(3):271-84.
25. Hancock RE, Sahl H-G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nature biotechnology. 2006;24(12):1551-7.
26. Doyle MP, Buchanan RL. Food microbiology: fundamentals and frontiers: American Society for Microbiology Press; 2012.
27. Molin G. 13 The Role of Lactobacillus plantarum in Foods and in Human Health. Handbook of Fermented Functional Foods. 2003:305.
28. Ghosh AR. Appraisal of probiotics and prebiotics in gastrointestinal infections. 2012.
29. Schiffrin EJ, Parlesak A, Bode C, Bode JC, van't Hof MA, Grathwohl D, et al. Probiotic yogurt in the elderly with intestinal bacterial overgrowth: endotoxaemia and innate immune functions. British journal of nutrition. 2009;101(07):961-6.
30. Wisselink H, Weusthuis R, Eggink G, Hugenholtz J, Grobben G. Mannitol production by lactic acid bacteria: a review. International Dairy Journal. 2002;12(2):151-61.
31. Hirayama T. Association between alcohol consumption and cancer of the sigmoid colon: observations from a Japanese cohort study. The Lancet. 1989;334(8665):725-7.
32. Kashmiri Z, Mankar S. Free radicals and oxidative stress in bacteria. Int J Curr Microbiol App Sci. 2014;3:34-40.
33. Rezaie A, Nikfar S, Abdollahi M. The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis. Archives of Medical Science. 2010;6(1):49-55.
34. Quigley EM, Quera R. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology. 2006;130(2 Suppl 1):S78-90.
35. Nascimento GG, Locatelli J, Freitas PC, Silva GL. Antibacterial activity of plant extracts and phytochemicals on antibiotic-resistant bacteria. Brazilian journal of microbiology. 2000;31(4):247-56.
36. Linskens R, Huijsdens X, Savelkoul P, Vandenbroucke-Grauls C, Meuwissen S. The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scandinavian Journal of Gastroenterology. 2001;36(234):29-40.
37. Bereswill S, Muñoz M, Fischer A, Plickert R, Haag L-M, Otto B, et al. Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PloS one. 2010;5(12):e15099.
2. Korhonen H, Pihlanto A. Bioactive peptides: production and functionality. International dairy journal. 2006;16(9):945-60.
3. Sharma S, Singh R, Rana S. Bioactive peptides: a review. Int J Bioautomation. 2011;15(4):223-50.
4. Korhonen H. Milk-derived bioactive peptides: From science to applications. Journal of Functional Foods. 2009;1(2):177-87.
5. Scalbert A, Morand C, Manach C, Rémésy C. Absorption and metabolism of polyphenols in the gut and impact on health. Biomedicine & Pharmacotherapy. 2002;56(6):276-82.
6. Cardona F, Andrés-Lacueva C, Tulipani S, Tinahones FJ, Queipo-Ortuño MI. Benefits of polyphenols on gut microbiota and implications in human health. The Journal of nutritional biochemistry. 2013;24(8):1415-22.
7. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food sources and bioavailability. The American journal of clinical nutrition. 2004;79(5):727-47.
8. Déprez S, Brezillon C, Rabot S, Philippe C, Mila I, Lapierre C, et al. Polymeric proanthocyanidins are catabolized by human colonic microflora into low-molecular-weight phenolic acids. The Journal of nutrition. 2000;130(11):2733-8.
9. Takahashi M, Moriguchi S, Yoshikawa M, Sasaki R. Isolation and characterization of oryzatensin: a novel bioactive peptide with ileum-contracting and immunomodulating activities derived from rice albumin. Biochemistry and molecular biology international. 1994;33(6):1151-8.
10. Ohinata K, Suetsugu K, Fujiwara Y, Yoshikawa M. Suppression of food intake by a complement C3a agonist [Trp 5]-oryzatensin (5–9). Peptides. 2007;28(3):602-6.
11. Ohinata K, Yoshikawa M. Food intake regulation by central complement system. Current Topics in Complement II: Springer; 2008. p. 33-44.
12. Asakura H, Suzuki K, Kitahora T, Morizane T. Is there a link between food and intestinal microbes and the occurrence of Crohn's disease and ulcerative colitis? Journal of gastroenterology and hepatology. 2008;23(12):1794-801.
13. Marteau PR, de Vrese M, Cellier CJ, Schrezenmeir J. Protection from gastrointestinal diseases with the use of probiotics. The American journal of clinical nutrition. 2001;73(2):430s-6s.
14. Husebye E. The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy. 2005;51(Suppl. 1):1-22.
15. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. The American journal of gastroenterology. 2000;95(12):3503-6.
16. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? The American journal of clinical nutrition. 2006;83(6):1256-64.
17. Zeng M, Cui W, Zhao Y, Liu Z, Dong S, Guo Y. Antiviral active peptide from oyster. Chinese Journal of Oceanology and Limnology. 2008;26:307-12.
18. Gill HS, Doull F, Rutherfurd K, Cross M. Immunoregulatory peptides in bovine milk. British Journal of Nutrition. 2000;84(S1):111-7.
19. Pierce A, Legrand D, Mazurier J. Lactoferrin: a multifunctional protein. Medecine sciences: M/S. 2009;25(4):361-9.
20. Seelinger G, Merfort I, Wölfle U, Schempp CM. Anti-carcinogenic effects of the flavonoid luteolin. Molecules. 2008;13(10):2628-51.
21. McIntosh GH, Royle PJ, Le Leu RK, Regester GO, Johnson MA, Grinsted RL, et al. Whey proteins as functional food ingredients? International Dairy Journal. 1998;8(5):425-34.
22. Agyei D, Danquah MK. Industrial-scale manufacturing of pharmaceutical-grade bioactive peptides. Biotechnology Advances. 2011;29(3):272-7.
23. Takahashi M, Moriguchi S, Ikeno M, Kono S, Ohata K, Usui H, et al. Studies on the ileum-contracting mechanisms and identification as a complement C3a receptor agonist of oryzatensin, a bioactive peptide derived from rice albumin. Peptides. 1996;17(1):5-12.
24. Marshall SH, Arenas G. Antimicrobial peptides: A natural alternative to chemical antibiotics and a potential for applied biotechnology. Electronic Journal of Biotechnology. 2003;6(3):271-84.
25. Hancock RE, Sahl H-G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nature biotechnology. 2006;24(12):1551-7.
26. Doyle MP, Buchanan RL. Food microbiology: fundamentals and frontiers: American Society for Microbiology Press; 2012.
27. Molin G. 13 The Role of Lactobacillus plantarum in Foods and in Human Health. Handbook of Fermented Functional Foods. 2003:305.
28. Ghosh AR. Appraisal of probiotics and prebiotics in gastrointestinal infections. 2012.
29. Schiffrin EJ, Parlesak A, Bode C, Bode JC, van't Hof MA, Grathwohl D, et al. Probiotic yogurt in the elderly with intestinal bacterial overgrowth: endotoxaemia and innate immune functions. British journal of nutrition. 2009;101(07):961-6.
30. Wisselink H, Weusthuis R, Eggink G, Hugenholtz J, Grobben G. Mannitol production by lactic acid bacteria: a review. International Dairy Journal. 2002;12(2):151-61.
31. Hirayama T. Association between alcohol consumption and cancer of the sigmoid colon: observations from a Japanese cohort study. The Lancet. 1989;334(8665):725-7.
32. Kashmiri Z, Mankar S. Free radicals and oxidative stress in bacteria. Int J Curr Microbiol App Sci. 2014;3:34-40.
33. Rezaie A, Nikfar S, Abdollahi M. The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis. Archives of Medical Science. 2010;6(1):49-55.
34. Quigley EM, Quera R. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology. 2006;130(2 Suppl 1):S78-90.
35. Nascimento GG, Locatelli J, Freitas PC, Silva GL. Antibacterial activity of plant extracts and phytochemicals on antibiotic-resistant bacteria. Brazilian journal of microbiology. 2000;31(4):247-56.
36. Linskens R, Huijsdens X, Savelkoul P, Vandenbroucke-Grauls C, Meuwissen S. The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scandinavian Journal of Gastroenterology. 2001;36(234):29-40.
37. Bereswill S, Muñoz M, Fischer A, Plickert R, Haag L-M, Otto B, et al. Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PloS one. 2010;5(12):e15099.
| Files | ||
| Issue | Vol 3, No 2 (Spring 2017) | |
| Section | Original Article(s) | |
| Keywords | ||
| Oryzatensin gut microbiota rice standard curve-fitting bio-active peptides neoplasm | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Alizadeh Sani M, Aynehchi A, Barati M, Ghavami A, Nattagh Eshtivani E, MokariYamchi A, Vaghef-Mehrabany E, Ebrahimi-Mameghani M. Investigating the effects of oryzatensin on gut microbiota growth using a novel quantitative standard curve-fitting method: an ex-vivo study. J Nutr Sci & Diet. 2017;3(2):28-34.
